chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Vaccination complication
Clinical narrative: Covid arm 7 days after each dose/Localized allergic reaction; Very hot; Red; Throbbing; Localized allergic reaction; A little bit lightheaded; Rash; This spontaneous case was reported by a pharmacist and describes the occurrence of VACCINATION COMPLICATION (Covid arm 7 days after each dose/Localized allergic reaction), FEELING HOT (Very hot), ERYTHEMA (Red), PAIN (Throbbing) and ALLERGY TO VACCINE (Localized allergic reaction) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was reported.  Concomitant products included ACETYLSALICYLIC ACID (ASPIRINE) for an unknown indication.    On 24-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (Covid arm 7 days after each dose/Localized allergic reaction), FEELING HOT (Very hot), ERYTHEMA (Red), PAIN (Throbbing), ALLERGY TO VACCINE (Localized allergic reaction), DIZZINESS (A little bit lightheaded) and RASH (Rash). The patient was treated with Manual therapy for Pain. At the time of the report, VACCINATION COMPLICATION (Covid arm 7 days after each dose/Localized allergic reaction), FEELING HOT (Very hot), ERYTHEMA (Red), PAIN (Throbbing), ALLERGY TO VACCINE (Localized allergic reaction), DIZZINESS (A little bit lightheaded) and RASH (Rash) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment information was not provided by the reporter.   This case was linked to MOD-2021-288404 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Dysphonia, Extra dose administered, Fatigue, Oropharyngeal pain, Pyrexia
Clinical narrative: heavy voice; sore throat; fever; fatigue; Extra dose administered; This spontaneous case was reported by a consumer and describes the occurrence of DYSPHONIA (heavy voice), OROPHARYNGEAL PAIN (sore throat), EXTRA DOSE ADMINISTERED (Extra dose administered), PYREXIA (fever) and FATIGUE (fatigue) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066D21A) for COVID-19 vaccination.     Concomitant products included EFINACONAZOLE (JUBLIA), ATORVASTATIN, GLIPIZIDE, METFORMIN, DOLUTEGRAVIR SODIUM (TIVICAY), FEBUXOSTAT and LORAZEPAM for an unknown indication.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 15-Aug-2021, the patient experienced EXTRA DOSE ADMINISTERED (Extra dose administered). On 16-Aug-2021, the patient experienced DYSPHONIA (heavy voice), OROPHARYNGEAL PAIN (sore throat), PYREXIA (fever) and FATIGUE (fatigue). At the time of the report, DYSPHONIA (heavy voice), OROPHARYNGEAL PAIN (sore throat), EXTRA DOSE ADMINISTERED (Extra dose administered), PYREXIA (fever) and FATIGUE (fatigue) outcome was unknown.            Treatment information was also not reported.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Feeling hot, Pyrexia, Rash, Swelling
Clinical narrative: right arm was tender to touch; was a little puffy, swelling; red; hot; rash; feverish; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (right arm was tender to touch), SWELLING (was a little puffy, swelling), ERYTHEMA (red), FEELING HOT (hot) and RASH (rash) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051D21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 06-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Aug-2021, the patient experienced TENDERNESS (right arm was tender to touch), SWELLING (was a little puffy, swelling), ERYTHEMA (red), FEELING HOT (hot), RASH (rash) and PYREXIA (feverish). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, TENDERNESS (right arm was tender to touch), SWELLING (was a little puffy, swelling), ERYTHEMA (red), FEELING HOT (hot), RASH (rash) and PYREXIA (feverish) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.
Age: 54.0
Sex: F
Vaccine: COVID19
Symptoms: Tenderness
Clinical narrative: right arm was tender to touch; was a little puffy, swelling; red; hot; rash; feverish; This spontaneous case was reported by a consumer and describes the occurrence of TENDERNESS (right arm was tender to touch), SWELLING (was a little puffy, swelling), ERYTHEMA (red), FEELING HOT (hot) and RASH (rash) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051D21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 06-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Aug-2021, the patient experienced TENDERNESS (right arm was tender to touch), SWELLING (was a little puffy, swelling), ERYTHEMA (red), FEELING HOT (hot), RASH (rash) and PYREXIA (feverish). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) ongoing since an unknown date at an unspecified dose and frequency. At the time of the report, TENDERNESS (right arm was tender to touch), SWELLING (was a little puffy, swelling), ERYTHEMA (red), FEELING HOT (hot), RASH (rash) and PYREXIA (feverish) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.
Age: 13.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: A 13 year old patient received 1st dose of moderna vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 13 year old patient received 1st dose of moderna vaccine) in a 13-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 019B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Aug-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 13 year old patient received 1st dose of moderna vaccine). On 16-Aug-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A 13 year old patient received 1st dose of moderna vaccine) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   the concomitant medication ware not provided the treatment medication s was not provided
Age: 24.0
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Vial that had been punctured 24 hours and 6 minutes before administration; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vial that had been punctured 24 hours and 6 minutes before administration) in a 24-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006D21A) for COVID-19 vaccination.     No Medical History information was reported.   On 16-Aug-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vial that had been punctured 24 hours and 6 minutes before administration). On 16-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Vial that had been punctured 24 hours and 6 minutes before administration) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment information was reported.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Interchange of vaccine products
Clinical narrative: received J&J vaccine 4 days after receiving first dose of Modernna; This spontaneous case was reported by a pharmacist and describes the occurrence of INTERCHANGE OF VACCINE PRODUCTS (received J&J vaccine 4 days after receiving first dose of Modernna) in a 68-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 059E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Aug-2021, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (received J&J vaccine 4 days after receiving first dose of Modernna). At the time of the report, INTERCHANGE OF VACCINE PRODUCTS (received J&J vaccine 4 days after receiving first dose of Modernna) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment medications were reported. He administered the MODERNA vaccine to a patient on 12Aug2021. He wasn't able to enter it in the system right away
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: they have a patient who got their first dose in January of 2021 and have not gotten their 2nd dose; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (they have a patient who got their first dose in January of 2021 and have not gotten their 2nd dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (they have a patient who got their first dose in January of 2021 and have not gotten their 2nd dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (they have a patient who got their first dose in January of 2021 and have not gotten their 2nd dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not provided.  Treatment information was not provided.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia
Clinical narrative: About two weeks later, I started having significant pain in my left hip joint; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (About two weeks later, I started having significant pain in my left hip joint) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 02SL20A and 032L20A) for COVID-19 vaccination.     Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID), ATORVASTATIN and ATENOLOL for an unknown indication.   On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ARTHRALGIA (About two weeks later, I started having significant pain in my left hip joint). At the time of the report, ARTHRALGIA (About two weeks later, I started having significant pain in my left hip joint) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication not provided. Concomitant drug is given as Olm ned flesh hctz 40-25 but drug code was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: follow up received and Patient street address and city  and Postal code and Date of birth details was added, patient info added, Drug information added, concomitant drugs added
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site swelling, Vaccination site warmth
Clinical narrative: injection site warm to touch; Injection site redness; Injection site swollen up; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (injection site warm to touch), VACCINATION SITE ERYTHEMA (Injection site redness) and VACCINATION SITE SWELLING (Injection site swollen up) in a 58-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 091D21A) for COVID-19 vaccination.     No Medical history was reported by the reporter.  Concomitant products included APIXABAN (ELIQUIS), FLECAINIDE, KETOROLAC TROMETHAMINE (TORADOL), POTASSIUM CHLORIDE, ATORVASTATIN, HYDROCHLOROTHIAZIDE, TRIAMTERENE (TRIAMTERENE/HCTZ) and PREGABALIN for an unknown indication.    On 14-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE WARMTH (injection site warm to touch), VACCINATION SITE ERYTHEMA (Injection site redness) and VACCINATION SITE SWELLING (Injection site swollen up). At the time of the report, VACCINATION SITE WARMTH (injection site warm to touch), VACCINATION SITE ERYTHEMA (Injection site redness) and VACCINATION SITE SWELLING (Injection site swollen up) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered, Product storage error
Clinical narrative: Expired vaccine administered/Vaccine administered after it was expired; Vaccine taken out of Fridge drawn up and put back, syringe was given chance to warm up a bit; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered/Vaccine administered after it was expired) and PRODUCT STORAGE ERROR (Vaccine taken out of Fridge drawn up and put back, syringe was given chance to warm up a bit) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006D21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered/Vaccine administered after it was expired) and PRODUCT STORAGE ERROR (Vaccine taken out of Fridge drawn up and put back, syringe was given chance to warm up a bit). On 06-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine administered/Vaccine administered after it was expired) and PRODUCT STORAGE ERROR (Vaccine taken out of Fridge drawn up and put back, syringe was given chance to warm up a bit) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  On 06 Aug 2021 at 2:15pm, the patient received after being expired.  No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Vaccine administered to 7 patients beyond 30 days; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine administered to 7 patients beyond 30 days) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 034C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 17-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine administered to 7 patients beyond 30 days). On 17-Aug-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine administered to 7 patients beyond 30 days) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications was reported.  No treatment medications was reported.
Sex: U
Vaccine: COVID19
Symptoms: Blood pressure increased
Clinical narrative: High blood pressure since they got the vaccine; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of BLOOD PRESSURE INCREASED (since they got the vaccine) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced BLOOD PRESSURE INCREASED. At the time of the report, BLOOD PRESSURE INCREASED (since they got the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was unknown.       Concomitant medications were not provided. Treatment information was not reported.    This case was linked to MOD-2021-131922 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: 1st dose given 18Jun2021; no 2nd dose yet; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (1st dose given 18Jun2021; no 2nd dose yet) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 054C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 17-Aug-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (1st dose given 18Jun2021; no 2nd dose yet). At the time of the report, PRODUCT DOSE OMISSION ISSUE (1st dose given 18Jun2021; no 2nd dose yet) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication reported . No treatment medication reported . No lab data provided by reporter .
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Body temperature, Chills, Extra dose administered, Headache
Clinical narrative: Fever/104 degrees F/102 degrees F/99.9 degrees F; Chills; Headache; Joint pain; Arm at the injection site was a little sore; Sweating; Received third dose on 17/Aug/2021; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Sweating), EXTRA DOSE ADMINISTERED (Received third dose on 17/Aug/2021), PYREXIA (Fever/104 degrees F/102 degrees F/99.9 degrees F), CHILLS (Chills) and HEADACHE (Headache) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A, 007M20A and 054C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Quadruple vessel bypass graft. Concurrent medical conditions included Diabetes.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Aug-2021, the patient experienced EXTRA DOSE ADMINISTERED (Received third dose on 17/Aug/2021). On 18-Aug-2021, the patient experienced HYPERHIDROSIS (Sweating), PYREXIA (Fever/104 degrees F/102 degrees F/99.9 degrees F), CHILLS (Chills), HEADACHE (Headache), ARTHRALGIA (Joint pain) and VACCINATION SITE PAIN (Arm at the injection site was a little sore). On 17-Aug-2021, EXTRA DOSE ADMINISTERED (Received third dose on 17/Aug/2021) had resolved. On 18-Aug-2021, HYPERHIDROSIS (Sweating), CHILLS (Chills) and ARTHRALGIA (Joint pain) had resolved. At the time of the report, PYREXIA (Fever/104 degrees F/102 degrees F/99.9 degrees F), HEADACHE (Headache) and VACCINATION SITE PAIN (Arm at the injection site was a little sore) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Aug-2021, Body temperature: 104 (High) 104 degrees Fahrenheit., 102 (High) 102 degrees Fahrenheit. and 99.9 (High) 99.9 degrees Fahrenheit..         No concomitant medication was reported.  The treatment information was not reported.
Age: 74.0
Sex: M
Vaccine: COVID19
Symptoms: Hyperhidrosis, Pyrexia, Vaccination site pain
Clinical narrative: Fever/104 degrees F/102 degrees F/99.9 degrees F; Chills; Headache; Joint pain; Arm at the injection site was a little sore; Sweating; Received third dose on 17/Aug/2021; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Sweating), EXTRA DOSE ADMINISTERED (Received third dose on 17/Aug/2021), PYREXIA (Fever/104 degrees F/102 degrees F/99.9 degrees F), CHILLS (Chills) and HEADACHE (Headache) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 042L20A, 007M20A and 054C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Quadruple vessel bypass graft. Concurrent medical conditions included Diabetes.   On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Aug-2021, the patient experienced EXTRA DOSE ADMINISTERED (Received third dose on 17/Aug/2021). On 18-Aug-2021, the patient experienced HYPERHIDROSIS (Sweating), PYREXIA (Fever/104 degrees F/102 degrees F/99.9 degrees F), CHILLS (Chills), HEADACHE (Headache), ARTHRALGIA (Joint pain) and VACCINATION SITE PAIN (Arm at the injection site was a little sore). On 17-Aug-2021, EXTRA DOSE ADMINISTERED (Received third dose on 17/Aug/2021) had resolved. On 18-Aug-2021, HYPERHIDROSIS (Sweating), CHILLS (Chills) and ARTHRALGIA (Joint pain) had resolved. At the time of the report, PYREXIA (Fever/104 degrees F/102 degrees F/99.9 degrees F), HEADACHE (Headache) and VACCINATION SITE PAIN (Arm at the injection site was a little sore) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 18-Aug-2021, Body temperature: 104 (High) 104 degrees Fahrenheit., 102 (High) 102 degrees Fahrenheit. and 99.9 (High) 99.9 degrees Fahrenheit..         No concomitant medication was reported.  The treatment information was not reported.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle spasms, Pain, Vaccination site pain
Clinical narrative: Concerned about the pain that comes from elbow to shoulder; Cramps in it sometimes; Pain in the left arm/Pain is between left elbow and shoulder/Pain is constant in the arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Concerned about the pain that comes from elbow to shoulder), MUSCLE SPASMS (Cramps in it sometimes) and VACCINATION SITE PAIN (Pain in the left arm/Pain is between left elbow and shoulder/Pain is constant in the arm) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038A21A) for COVID-19 vaccination.     No Medical History was provided.     On 08-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN (Concerned about the pain that comes from elbow to shoulder), MUSCLE SPASMS (Cramps in it sometimes) and VACCINATION SITE PAIN (Pain in the left arm/Pain is between left elbow and shoulder/Pain is constant in the arm). At the time of the report, PAIN (Concerned about the pain that comes from elbow to shoulder), MUSCLE SPASMS (Cramps in it sometimes) and VACCINATION SITE PAIN (Pain in the left arm/Pain is between left elbow and shoulder/Pain is constant in the arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant Medications were provided. No Treatment Medications were provided.   This case was linked to MOD-2021-291290 (Patient Link).
Sex: M
Vaccine: COVID19
Symptoms: Chills, Dizziness, Feeling abnormal, Pyrexia
Clinical narrative: Dizziness; Felt miserable; Fever; Chills; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), FEELING ABNORMAL (Felt miserable), PYREXIA (Fever) and CHILLS (Chills) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced DIZZINESS (Dizziness), FEELING ABNORMAL (Felt miserable), PYREXIA (Fever) and CHILLS (Chills). At the time of the report, DIZZINESS (Dizziness), FEELING ABNORMAL (Felt miserable), PYREXIA (Fever) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication details were provided. No treatment information was mentioned.   Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: I currently have COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (I currently have COVID-19) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to at an unspecified dose. On an unknown date, the patient experienced COVID-19 (I currently have COVID-19). At the time of the report, COVID-19 (I currently have COVID-19) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications was not provided by the reporter. Treatment information was not provided.  It was reported that the patient was about to get second Moderno shot on August 22.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Myalgia, Pain, Product dose omission issue, Pyrexia
Clinical narrative: Contracted Covid-19 infection; Pain; Felt achy; Fever; but she did not get her second dose; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Contracted Covid-19 infection), PAIN (Pain), MYALGIA (Felt achy), PYREXIA (Fever) and PRODUCT DOSE OMISSION ISSUE (but she did not get her second dose) in an 87-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (Contracted Covid-19 infection), PAIN (Pain), MYALGIA (Felt achy), PYREXIA (Fever) and PRODUCT DOSE OMISSION ISSUE (but she did not get her second dose). At the time of the report, COVID-19 (Contracted Covid-19 infection), PAIN (Pain), MYALGIA (Felt achy), PYREXIA (Fever) and PRODUCT DOSE OMISSION ISSUE (but she did not get her second dose) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was withdrawn on an unknown date.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
Sex: F
Vaccine: COVID19
Symptoms: White blood cell count, White blood cell count decreased
Clinical narrative: White Blood Cell count was low; This spontaneous case was reported by a consumer and describes the occurrence of WHITE BLOOD CELL COUNT DECREASED (White Blood Cell count was low) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included LORAZEPAM and COLECALCIFEROL (VITAMIN D3) for an unknown indication, VITAMIN C [ASCORBIC ACID] and EMERGEN C.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced WHITE BLOOD CELL COUNT DECREASED (White Blood Cell count was low). At the time of the report, WHITE BLOOD CELL COUNT DECREASED (White Blood Cell count was low) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, White blood cell count: low (Low) Low.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment medication was reported by patient.
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Induration, Nasal discomfort, Nodule
Clinical narrative: Redness; Pain along left nasolabial fold with soreness; Nodule; Firmness; This spontaneous case was reported by a physician and describes the occurrence of ERYTHEMA (Redness), NASAL DISCOMFORT (Pain along left nasolabial fold with soreness), NODULE (Nodule) and INDURATION (Firmness) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Skin cancer and Surgery (The vulva area removed due to skin cancer). Concurrent medical conditions included Rosacea.   On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Apr-2021, the patient experienced ERYTHEMA (Redness), NASAL DISCOMFORT (Pain along left nasolabial fold with soreness), NODULE (Nodule) and INDURATION (Firmness). The patient was treated with PREDNISONE at a dose of 1 dosage form; AMOXICILLIN, CLAVULANIC ACID (AUGMENTIN [AMOXICILLIN;CLAVULANIC ACID]) at a dose of 1 dosage form and HYALURONIDASE (VITRASE) at a dose of 1 dosage form. On 24-Jun-2021, ERYTHEMA (Redness), NASAL DISCOMFORT (Pain along left nasolabial fold with soreness), NODULE (Nodule) and INDURATION (Firmness) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication was not provided  Pt received 2doses of COVID-19 vaccinations but the manufacturer was unknown.   Due to skin cancer the vulva area removed two weeks prior to Lyft injection and had been on antibiotics for a vaginal infection post-surgery. Patient was injected with 1cc total of Restylane Lyft in both cheeks on 23-Apr-2021.
Sex: F
Vaccine: COVID19
Symptoms: Chills, Intentional product use issue, Malaise, Myalgia, Pyrexia
Clinical narrative: More than 42 days for administration of second dose; Wasn't feeling good; Fever; Chills; Body aches; This spontaneous case was reported by a pharmacist and describes the occurrence of INTENTIONAL PRODUCT USE ISSUE (More than 42 days for administration of second dose), MALAISE (Wasn't feeling good), PYREXIA (Fever), CHILLS (Chills) and MYALGIA (Body aches) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INTENTIONAL PRODUCT USE ISSUE (More than 42 days for administration of second dose), MALAISE (Wasn't feeling good), PYREXIA (Fever), CHILLS (Chills) and MYALGIA (Body aches). At the time of the report, INTENTIONAL PRODUCT USE ISSUE (More than 42 days for administration of second dose) had resolved and MALAISE (Wasn't feeling good), PYREXIA (Fever), CHILLS (Chills) and MYALGIA (Body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The concomitant medications were not reported.  The treatment information was not provided.   Reporter did not allow further contact
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: today a vaccine was administered and it expired on August 11th; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (today a vaccine was administered and it expired on August 11th) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Aug-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (today a vaccine was administered and it expired on August 11th). On 18-Aug-2021, EXPIRED PRODUCT ADMINISTERED (today a vaccine was administered and it expired on August 11th) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported. No treatment information was provided.
Sex: U
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: adverse reaction; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (adverse reaction) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (adverse reaction). At the time of the report, VACCINATION COMPLICATION (adverse reaction) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Relevant concomitant medications were not provided. Treatment information was not provided.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: my arm was sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (my arm was sore) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced VACCINATION SITE PAIN (my arm was sore). At the time of the report, VACCINATION SITE PAIN (my arm was sore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient age was given as 13 may Concomitant medications were not provided Treatment medications were not provided   This case was linked to MOD-2021-291114, MOD-2021-291120 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Up to 23 patients received 2nd doses 30 days beyond the use by date; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Up to 23 patients received 2nd doses 30 days beyond the use by date) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Up to 23 patients received 2nd doses 30 days beyond the use by date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Up to 23 patients received 2nd doses 30 days beyond the use by date) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided.  Treatment information was not provided.  The reporter was a clinic supervisor. His clinic administered up to 23 injections, all 2nd doses beyond the 30 day refrigeration window. The doses came from 2 vials, both with same lot number and expiration date. The vials did not undergo a prior temperature excursion. He did not have the date when they were placed in the freezer.  The vials came from McKesson frozen and were removed from freezer and placed in the refrigerator on 12-Apr-2021 where they were stored from 40F to 41F until administered.  None of the doses were kept at room temperature. They were removed from the refrigerator and immediately given to patients. Ten 2nd doses were administered on 26-May-2021 and 11 or more 2nd doses were administered on 23-Jun-2021. All patients received the shots via the same route of administration. The vials were currently stored in the refrigerator awaiting destruction. Upon visual inspection, the vials looked normal.
Sex: F
Vaccine: COVID19
Symptoms: Ear discomfort, Extra dose administered
Clinical narrative: It kind of seems like there is water in my ear; Extra dose administered; This spontaneous case was reported by a consumer and describes the occurrence of EAR DISCOMFORT (It kind of seems like there is water in my ear) and EXTRA DOSE ADMINISTERED (Extra dose administered) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Aug-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Aug-2021, the patient experienced EXTRA DOSE ADMINISTERED (Extra dose administered). On 17-Aug-2021, the patient experienced EAR DISCOMFORT (It kind of seems like there is water in my ear). On 16-Aug-2021, EXTRA DOSE ADMINISTERED (Extra dose administered) had resolved. At the time of the report, EAR DISCOMFORT (It kind of seems like there is water in my ear) had not resolved.            No concomitant medication provided. No treatment information mentioned. After the second shot, the patient had 3 rounds of steroids plus 3 injections to treat the symptom. After six months the hearing started to get better, like 30% better, until the third dose was given and the problem started again.   This case was linked to MOD-2021-103664.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered, Fatigue, Myalgia
Clinical narrative: sore arm; tiredness; Inadvertent administration of more than 2 doses; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (sore arm), FATIGUE (tiredness) and EXTRA DOSE ADMINISTERED (Inadvertent administration of more than 2 doses) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Aug-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Aug-2021, the patient experienced MYALGIA (sore arm), FATIGUE (tiredness) and EXTRA DOSE ADMINISTERED (Inadvertent administration of more than 2 doses). On 13-Aug-2021, EXTRA DOSE ADMINISTERED (Inadvertent administration of more than 2 doses) had resolved. At the time of the report, MYALGIA (sore arm) and FATIGUE (tiredness) outcome was unknown.            No concomitant medication was provided. No treatment medication was given.    This case was linked to MOD-2021-291115 (Patient Link).
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Body temperature increased, Myalgia
Clinical narrative: Rise in temperature; She had pains in her body; This spontaneous case was reported by a consumer and describes the occurrence of BODY TEMPERATURE INCREASED (Rise in temperature) and MYALGIA (She had pains in her body) in a 50-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for an unreported indication: EPINEPHRINE (Her doctor prescribed epinephrine injection before she went to take the shot.). Concurrent medical conditions included Drug allergy (Ibuprofen) and Drug allergy (Anesthetic drugs).    On 18-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced BODY TEMPERATURE INCREASED (Rise in temperature) and MYALGIA (She had pains in her body). At the time of the report, BODY TEMPERATURE INCREASED (Rise in temperature) and MYALGIA (She had pains in her body) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: increased (High) a rise in temperature..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided by the reporter. Treatment information was not provided.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Vaccination site discolouration, Vaccination site pain, Vaccination site rash
Clinical narrative: discoloration; Achy where she got the shot; headachy; extremely tired; rash near where she got the shot/until the 8th day and it was of around 2 by 2 inches when it started, then it spread to 3 by 4 inches in area; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE DISCOLOURATION (discoloration), VACCINATION SITE PAIN (Achy where she got the shot), HEADACHE (headachy), FATIGUE (extremely tired) and VACCINATION SITE RASH (rash near where she got the shot/until the 8th day and it was of around 2 by 2 inches when it started, then it spread to 3 by 4 inches in area) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 052C21A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma and Rhinitis. Concomitant products included FLUTICASONE PROPIONATE (FLOVENT) for Asthma, AZELASTINE for Rhinitis, METOPROLOL for an unknown indication.    On 17-Jul-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Jul-2021, the patient experienced VACCINATION SITE RASH (rash near where she got the shot/until the 8th day and it was of around 2 by 2 inches when it started, then it spread to 3 by 4 inches in area). On an unknown date, the patient experienced VACCINATION SITE DISCOLOURATION (discoloration), VACCINATION SITE PAIN (Achy where she got the shot), HEADACHE (headachy) and FATIGUE (extremely tired). On 08-Aug-2021, VACCINATION SITE RASH (rash near where she got the shot/until the 8th day and it was of around 2 by 2 inches when it started, then it spread to 3 by 4 inches in area) had resolved. At the time of the report, VACCINATION SITE DISCOLOURATION (discoloration), VACCINATION SITE PAIN (Achy where she got the shot), HEADACHE (headachy) and FATIGUE (extremely tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment information was not provided.   This case was linked to MOD-2021-291328 (Patient Link).
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination complication
Clinical narrative: mild reaction to the Moderna COVID-19 vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (mild reaction to the Moderna COVID-19 vaccine) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028620A) for COVID-19 vaccination.     Concomitant products included PREDNISONE and FAMOTIDINE (PEPCID [FAMOTIDINE]) for an unknown indication.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (mild reaction to the Moderna COVID-19 vaccine). At the time of the report, VACCINATION COMPLICATION (mild reaction to the Moderna COVID-19 vaccine) outcome was unknown.            No treatment information was provided by the reporter.   This case was linked to MOD-2021-291124 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Dyspnoea, Feeling abnormal, Yawning
Clinical narrative: Been freaking out; I can breath but can't catch that last breath IN and been yawning a lot since thursday; I can breath but can't catch that last breath IN and been yawning a lot since thursday; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (Been freaking out), DYSPNOEA (since thursday), and YAWNING (since thursday) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Heart disease, unspecified and Asthma.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (Been freaking out), DYSPNOEA (since thursday) and YAWNING (since thursday). At the time of the report, FEELING ABNORMAL (Been freaking out), DYSPNOEA (since thursday) and YAWNING (since thursday) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) was unknown.       The concomitant history was not reported. The treatment history was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 17-Aug-2021: Follow-up information received on 17-AUG-2021 contains significant information. Medical history information is reported. On 18-Aug-2021: Follow-up information received on 17-AUG-2021 contains significant information. Event information that the yawning is still ongoing. On 18-Aug-2021: Follow-up information received on 17-AUG-2021 contains significant information. Another Medical history Asthma is reported.